Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world camrelizumab plus apatinib in unresectable hepatocellular carcinoma
ChiCTR2200061972Phase 4Recruiting
- Sponsor
- Mengchao Hepatobiliary Hospital of Fujian Medical University
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Mengchao Hepatobiliary Hospital of Fujian Medical University. Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200061972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061972.